Biogen's Trading Volume Surges to $254 Million, Ranked 334th Amidst Stock Decline

On April 2, 2025, Biogen's trading volume reached $254 million, marking a 41.01% increase from the previous day. This surge placed Biogen at the 334th position in terms of trading volume for the day. However, the stock has been on a downward trend, falling 0.54% and experiencing a 7.80% decline over the past five days.

Biogen's investigational antisense oligonucleotide therapy, BIIB080, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). This therapy is designed to target microtubule-associated protein tau (MAPT) mRNA, aiming to reduce the production of tau protein, which is implicated in Alzheimer's disease. BIIB080 is the first tau-targeting antisense oligonucleotide to enter clinical development for Alzheimer's disease and is currently being evaluated in the global Phase 2 CELIA study.

The FDA's Fast Track designation for BIIB080 is a significant validation of Biogen's approach to targeting tau pathology in Alzheimer's disease. This designation is intended to expedite the development and review of investigational drugs that address serious conditions and unmet medical needs. The decision was based on results from a Phase 1b study, which showed dose-dependent reductions in soluble tau protein in cerebrospinal fluid.

Biogen's Head of Development, Priya Singhal, M.D., M.P.H., expressed encouragement over the FDA's Fast Track designation for BIIB080, emphasizing the urgent need for innovative treatments targeting tau pathology in Alzheimer's disease. Singhal noted that Alzheimer's is a complex and fatal disease that may require multiple therapeutic approaches to address its diverse pathologies. BIIB080 represents a differentiated approach to targeting tau, with promising potential for patients. Biogen is advancing this program with urgency on behalf of people living with Alzheimer's and their families.